Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
Olaparib as adjuvant treatment could be cost-effective in gBRCAm patients with early HER2neg BC in Spain.
Authors
- Yoana Ivanova-Markova
- Sergio Cedillo (ORCID: https://orcid.org/0009-0000-1378-1625)
- Sara López‐Tarruella (ORCID: https://orcid.org/0000-0002-2606-9538)
- José Alberto Peña Pedrosa
- Almudena González‐Domínguez (ORCID: https://orcid.org/0000-0002-3509-0961)
- Rafael López López
Institutions
- Weber State University (US)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Clínico San Carlos (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- AstraZeneca (Spain) (ES)
- Weber (ES)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1007/s41669-024-00518-2
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- AstraZeneca
- AstraZeneca España